Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:25:27.954Z.
Calculation as of: 2026-10-06T13:25:27.954Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9de0dbfadb283a207fe687abae4d6c7414f83280ed3d33a9edf26fe3e5e7dd3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2015-01-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$819.44M
EBITDA Yield
N/A
TTM Avg
1.34%
3Y Avg
2.25%
5Y Avg
2.25%
Market Cap
$867.60M
EBITDA Yield
N/A
TTM Avg
3.15%
3Y Avg
3.15%
5Y Avg
3.15%
Market Cap
$786.48M
EBITDA Yield
N/A
TTM Avg
0.40%
3Y Avg
0.67%
5Y Avg
0.67%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $837.43M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | N/A | 1.34% | 2.25% | 2.25% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $812.20M | 16.62% | 14.19% | 12.45% | 9.40% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 3.15% | 3.15% | 3.15% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | N/A | 0.40% | 0.67% | 0.67% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 15.11% | 18.56% | 15.22% | 13.39% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2015-01-30 | 11.29% |
| 2015-01-29 | 10.26% |
| 2015-01-28 | 10.06% |
| 2015-01-27 | 17.00% |
| 2015-01-26 | 14.76% |
| 2015-01-23 | 12.56% |
| 2015-01-22 | 13.95% |
| 2015-01-21 | 25.63% |
| 2015-01-20 | 20.44% |
| 2015-01-16 | 18.91% |
| 2015-01-15 | 47.18% |
| 2015-01-14 | 45.08% |
| 2015-01-13 | 107.41% |
| 2015-01-12 | 120.20% |
| 2015-01-09 | 420.63% |
| 2015-01-08 | 296.93% |
| 2014-12-22 | 81.43% |
| 2014-12-19 | 88.57% |
| 2014-12-18 | 65.57% |
| 2014-12-17 | 2520.49% |
| 2014-12-12 | 5.82% |
| 2014-12-11 | 7.99% |
| 2014-12-10 | 7.57% |
| 2014-12-09 | 6.00% |
| 2014-12-08 | 5.42% |
| 2014-12-05 | 4.29% |
| 2014-12-04 | 4.33% |
| 2014-12-03 | 4.27% |
| 2014-12-02 | 6.99% |
| 2014-12-01 | 9.23% |
| 2014-11-28 | 12.11% |
| 2014-11-26 | 14.14% |
| 2014-11-25 | 81.43% |
| 2014-11-24 | 97.09% |
